NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 292 filers reported holding NOVOCURE LTD in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,561,396 | +198.9% | 1,706,588 | +668.0% | 0.14% | +209.1% |
Q2 2023 | $9,221,591 | +1317.4% | 222,207 | +1954.0% | 0.04% | +1366.7% |
Q1 2023 | $650,595 | -85.1% | 10,818 | -82.8% | 0.00% | -87.0% |
Q2 2022 | $4,366,000 | +28.4% | 62,818 | +53.1% | 0.02% | +21.1% |
Q1 2022 | $3,400,000 | -2.7% | 41,038 | -11.8% | 0.02% | 0.0% |
Q4 2021 | $3,493,000 | -36.0% | 46,518 | +89.1% | 0.02% | -50.0% |
Q2 2021 | $5,457,000 | -82.3% | 24,599 | -89.5% | 0.04% | -83.2% |
Q1 2021 | $30,895,000 | +0.9% | 233,734 | +32.1% | 0.23% | -12.1% |
Q4 2020 | $30,608,000 | +238.3% | 176,883 | +117.6% | 0.26% | +242.7% |
Q3 2020 | $9,047,000 | +250.3% | 81,277 | +86.6% | 0.08% | +150.0% |
Q2 2020 | $2,583,000 | -14.0% | 43,550 | +8.4% | 0.03% | -42.3% |
Q3 2019 | $3,004,000 | +62.7% | 40,173 | +37.6% | 0.05% | +2.0% |
Q2 2019 | $1,846,000 | -34.4% | 29,199 | -50.0% | 0.05% | -40.0% |
Q1 2019 | $2,812,000 | -8.6% | 58,386 | -40.6% | 0.08% | +3.7% |
Q2 2018 | $3,076,000 | – | 98,290 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |